about
In situ crosslinkable heparin-containing poly(ethylene glycol) hydrogels for sustained anticoagulant release.Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling.pH-responsive thiolated chitosan nanoparticles for oral low-molecular weight heparin delivery: in vitro and in vivo evaluation.Serpins in thrombosis, hemostasis and fibrinolysisHigh Hydrostatic Pressure Pretreatment of Whey Protein Isolates Improves Their Digestibility and Antioxidant CapacityNew challenges for a second-generation low-molecular-weight heparin: focus on bemiparin.Recent advances in search of oral heparin therapeutics.Formulation strategies to improve oral peptide delivery.Lipid polymer hybrid as emerging tool in nanocarriers for oral drug delivery.Engineered nanoparticles: thrombotic events in cancer.Recent advances in anticoagulant drug delivery.Preparation and characterization of self nano-emulsifying drug delivery system (SNEDDS) for oral delivery of heparin using hydrophobic complexation by cationic polymer of β-cyclodextrin.Preparation and evaluation of a novel oral delivery system for low molecular weight heparin.Enhanced antithrombotic effects of unfractionated heparin in rats after repeated oral doses and its relationship to endothelial heparin concentration.Oral delivery of low molecular weight heparin by polyaminomethacrylate coacervates.Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects.Oral Administration and Detection of a Near-Infrared Molecular Imaging Agent in an Orthotopic Mouse Model for Breast Cancer Screening.
P2860
Q33894433-E314343F-7419-4025-8AE6-48CA5E64B228Q35001659-B8A72B52-0055-4EF9-BBD8-BEA7B63A17D1Q35174709-965B54ED-61D0-4051-B244-4931CE64FD9CQ36884340-6F11D9C2-1D81-4DBE-91FB-762D15F39EC8Q37636000-98FC1BBC-69BD-4F2C-86E2-8BF74407FA1BQ37744931-D8508D57-B959-499B-9AA0-A00D207F5AA7Q37834507-92F5433D-1480-4C9B-93A8-D8C11938385FQ38226675-0D3DA791-930F-46FE-ACF7-85252A496497Q38252593-F69D4FFC-A19E-442C-87D7-B7FE53757BFFQ38262939-634FF54E-C3CD-4865-B516-547407598A06Q38649939-25A3561A-5722-4830-9047-FE3E1ECBE367Q38689886-67DFF1EB-7103-4585-9E9B-78A8FB2963D3Q41550747-044FE85C-ACD1-42B3-A48F-93D0CEAF087CQ43088071-A302AB5A-7FAD-40C7-B349-8D6BC3BC07BEQ47236567-7DCB2D80-E5FB-4205-8577-B51E6BE35461Q51764454-AC0531EB-7FDB-43C9-9FB6-729F0C3037C6Q52562051-2A8A8160-0B6D-4103-B777-840A796381CB
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Oral heparin: status review
@ast
Oral heparin: status review
@en
Oral heparin: status review
@nl
type
label
Oral heparin: status review
@ast
Oral heparin: status review
@en
Oral heparin: status review
@nl
prefLabel
Oral heparin: status review
@ast
Oral heparin: status review
@en
Oral heparin: status review
@nl
P2093
P2860
P356
P1433
P1476
Oral heparin: status review
@en
P2093
Ehud Arbit
Isabel Gomez-Orellana
Michael Goldberg
Shingai Majuru
P2860
P2888
P356
10.1186/1477-9560-4-6
P577
2006-05-10T00:00:00Z
P5875
P6179
1012094543